J&J bags option on AdoRx lung cancer drugs

AdoRx Therapeutics CEO Pete Finan. (AdoRx Therapeutics)

Johnson & Johnson is teaming up with AdoRx Therapeutics to develop lung cancer drugs. The deal gives J&J an exclusive option to research, develop and commercialize AdoRx antagonists.

AdoRx, a Scottish biotech, began operations in 2017 with a focus on discovering adenosine receptor antagonists that engage their targets in the adenosine-rich tumor microenvironment. That focus led AdoRx to embark on programs to discover drugs that block adenosine A2A or both A2A and A2B.

Epidarex Capital and CRT Pioneer Fund pumped an initial $10 million into AdoRx last summer but aside from that the startup has kept a low profile. Even so, AdoRx managed to capture the attention of J&J.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

The Big Pharma has secured an exclusive option on antagonists in development at AdoRx and the chance to collaborate with the startup on drug discovery and preclinical testing. Neither party has disclosed financial details of the deal. 

The deal forms part of J&J’s lung cancer initiative, which seeks to leverage its diversified business model to tackle the disease in different ways. Many drug development programs focus on patients with late-stage lung cancer. By involving its consumer, diagnostic and drug units, J&J hopes to find ways to prevent the disease or at least identify and treat it far earlier than happens today. 

So far, J&J’s publicly disclosed efforts have leaned toward diagnostics, most notably through the deals it has entered into with Boston University Medical Center and Veracyte over the past nine months. 

The AdoRx deal moves the lung cancer initiative into the treatment of the disease. Researchers have known for years that A2A receptors, targets best known in neurology contexts, are found on immune cells. That knowledge became more pertinent to cancer R&D teams as the immuno-oncology era got underway and interest in immune checkpoints skyrocketed. 

Today, companies including AstraZeneca and Novartis have moved A2A antagonists into the clinic in the belief they can spur the proliferation and activation of T lymphocytes and otherwise encourage antitumor immune attacks. 

Suggested Articles

Janssen is planning its first completely virtual clinical trial, using personal smartphones and wearable devices with no in-person site visits.

Sensyne Health aims to bring its AI tools to America, and it’s enlisting IT giant Cognizant and data infrastructure specialist Agorai to help.

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.